Create issue ticket

10,436 Possible Causes for 5, CTCAE, Disease, Grade, NOS, Progression

  • Relapsed Small Cell Lung Cancer

    : teniposide, 60 mg/m2, i.v. days 1-5, every 3 weeks until further progression.[ncbi.nlm.nih.gov] Adverse events (AEs) and laboratory abnormalities were graded with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4 [ 8 ] and coded[academic.oup.com] The most frequent toxicities were grade 2-3 neutropenia (27.8 % of patients), grade 2-3 anemia (33.3 %), grade 2 thrombocytopenia (16.7 %), and grade 2-3 fatigue (44.4 %).[ncbi.nlm.nih.gov] […] discuss ] [ citation needed ] In the tissue classification, the centural type contains about one-ninth. [ citation needed ] Sometimes the phrase "not otherwise specified", or NOS[en.wikipedia.org] PURPOSE: To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD[ncbi.nlm.nih.gov] In all 5 trials, patients received topotecan 1.5 mg/m2 per day via a 30-minute intravenous infusion on days 1 through 5 of a 21-day cycle.[ncbi.nlm.nih.gov]

  • Idiopathic Pulmonary Fibrosis

    Abstract Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease that is characterized by progressive and irreversible scarring of the lung.[ncbi.nlm.nih.gov] The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel.[ncbi.nlm.nih.gov] Fibrosis of lung (atrophic) (chronic) (confluent) (massive) (perialveolar) (peribronchial) NOS Induration of lung (chronic) NOS Postinflammatory pulmonary fibrosis idiopathic[icd10data.com] OBJECTIVE: A substantial proportion of cases of usual interstitial pneumonia (UIP) are due to connective tissue disease (CTD)-associated interstitial lung disease (ILD).[ncbi.nlm.nih.gov] Chen H 1 , Chen Q 2 , Jiang CM 3 , Shi GY 4 , Sui BW 5 , Zhang W 5 , Yang LZ 5 , Li ZY 5 , Liu L 5 , Su YM 5 , Zhao WC 3 , Sun HQ 3 , Li ZZ 6 , Fu Z 7 .[ncbi.nlm.nih.gov] However, accelerated disease progression after nintedanib discontinuation has never been reported.[ncbi.nlm.nih.gov]

    Missing: CTCAE
  • Peripheral T-cell Lymphoma

    […] from third progression (FFS3, OS3).[ncbi.nlm.nih.gov] 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3]).[ncbi.nlm.nih.gov] KEYWORDS: PTCL-NOS; lymphoma; myasthenia gravis; tacrolimus; thymectomy[ncbi.nlm.nih.gov] Abstract A 46-year-old man with a long-standing history of Crohn's disease who was treated with multiple therapies over a period of 9 years presented with oral lesions which[ncbi.nlm.nih.gov] Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles.[ncbi.nlm.nih.gov] PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with the best response of stable disease[ncbi.nlm.nih.gov]

    Missing: CTCAE
  • MALT Lymphoma

    There was no significant difference in the median time to progression (p 0.141), but the estimated time to progression (p 0.023) as well as the estimated time to next therapy[ncbi.nlm.nih.gov] Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), August 9, 2006. National Comprehensive Cancer Network: Google Scholar 22.[doi.org] The aim of this study was to investigate the long-term effect of treatment of low-grade gastric MALT lymphoma with the H. pylori eradication method.[ncbi.nlm.nih.gov] […] cancer genome data @ progenetix.org 427 samples from progenetix have an associated "ICDMORPHOLOGYCODE" label. 9699/3: Marginal zone B-cell lymphoma, NOS (M-96993) 25% 50%[progenetix.org] […] report describes etiologic data, diagnostic and treatment considerations, and sophisticated radiation therapy techniques aimed at reducing long-term toxicity in this indolent disease[ncbi.nlm.nih.gov] Abstract Minimal change disease (MCD) in association with low-grade extra-nodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) (MALT lymphoma[ncbi.nlm.nih.gov]

  • Anaplastic Astrocytoma

    Interpreting the overlapping radiologic and clinical characteristics of glial tumours, MS lesions, and progressive multifocal leukoencephalopathy (PML) can be a significant[ncbi.nlm.nih.gov] Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening. ] Adverse events were graded using CTCAE v2.0.[clinicaltrials.gov] Abstract Anaplastic astrocytoma is a high grade malignant glioma (WHO grade III) of the central nervous system which arises from a low grade II tumor and invariably progresses[ncbi.nlm.nih.gov] Anaplastic astrocytoma,NOS (ICD-O: 9401/3) - genetic data missing. Radiology/Clinic Mass effect. Seizures. Neurologic decifit.[librepathology.org] We are presenting a young patient with Ollier Disease and high-grade astrocytoma.[ncbi.nlm.nih.gov] Minniti G 1, 2 , Scaringi C 3 , Arcella A 4 , Lanzetta G 4 , Di Stefano D 5 , Scarpino S 5 , Bozzao A 6 , Pace A 7 , Villani V 7 , Salvati M 8 , Esposito V 4 , Giangaspero[ncbi.nlm.nih.gov]

  • Dementia

    Dementia progresses differently in everyone.[healthline.com] Two authors independently assessed and graded the methodology of all included studies.[ncbi.nlm.nih.gov] ; Dementia NOS; Epileptic Psychosis NOS; Mixed Paranoid and Affective Organic Psychotic States 299 - Pervasive Developmental Disorders 331 - Cerebral Degenerations, Other[web.archive.org] To determine which clinical features best characterize Parkinson disease dementia (PDD), compared with Alzheimer disease (AD) and dementia with Lewy bodies (DLB), and to determine[ncbi.nlm.nih.gov] The aim of this study was to describe the successful use of ECT in treating 5 patients with disruptive vocalization.[ncbi.nlm.nih.gov] Two generic evaluation tools based on WCAG2.0 were used to assess the accessibility of information on dementia and two readability tests (Flesh-Kincaid Grade level and SMOG[ncbi.nlm.nih.gov]

    Missing: CTCAE
  • Pseudomyxoma Peritonei

    […] rapid progression of PMCA may be due to larger numbers of these SICs. 2014 The Authors.[ncbi.nlm.nih.gov] Morbidity complications Grade 3 in the CTCAE v 3.0 classification was 18.4 %. One patient died 45 days postsurgery.[ncbi.nlm.nih.gov] Outside the spleen, a low-grade MCCa component was found. No ectopic pancreatic or intestinal tissue was identified.[ncbi.nlm.nih.gov] The most common malignancies were mucinous adenocarcinoma (38 %), followed by carcinoids (28 %), adenocarcinoma-not otherwise specified (NOS) (27 %), and signet ring cell[doi.org] Peritoneal gelatinous diseases must be subdivided into disseminated peritoneal adenomucinosis, peritoneal mucinous carcinomatosis and intermediate cases.[ncbi.nlm.nih.gov] The 5-year overall survival for the debulking-era group and the HIPEC-era group were 67 and 69 %, respectively.[ncbi.nlm.nih.gov]

  • Radiation Pneumonitis

    Therefore, we retrospectively analyzed the correlation of a history of radiation pneumonitis before nivolumab with onset of interstitial lung disease (ILD) and progression-free[ncbi.nlm.nih.gov] RP was diagnosed by chest X-ray or computed tomography after HRT, and its severity was determined by CTCAE version 4.0. The incidence of symptomatic RP was 26.6%.[ncbi.nlm.nih.gov] In this study, predictors of grade 2 and grade 3 RP were investigated separately.[ncbi.nlm.nih.gov] Bronchitis with tracheitis NOS Catarrhal bronchitis Tracheobronchitis NOS Type 1 Excludes acute bronchitis ( J20.- ) allergic bronchitis NOS ( J45.909- ) asthmatic bronchitis[icd10data.com] Abstract Gallium-67 scan is usually performed in patients with Hodgkin's disease and high-grade non-Hodgkin lymphoma for evaluation of disease status after treatment.[ncbi.nlm.nih.gov] To investigate the factors associated with Grade 5 radiation pneumonitis (G5 RP), several parameters were analyzed: (i) patient-specific factors (age, gross tumor volume and[ncbi.nlm.nih.gov]

  • B-Cell Lymphoma

    BACKGROUND: In patients presenting with rapidly progressive dementia, prion disease may enter the differential diagnosis.[ncbi.nlm.nih.gov] […] and posttreatment patients profile of blood chemistry, liver functions test was collected and compared with the Common Terminology Criteria for adverse events v3.0 2009 CTCAE[ncbi.nlm.nih.gov] […] high-grade B-cell component alone.[ncbi.nlm.nih.gov] […] listed in the World Health Organization classification of B-lymphoid neoplasms: Precursor B-lymphoid neoplasms B-lymphoblastic leukemia/lymphoma, not otherwise specified (NOS[symptoma.com] […] change of serum IgG4 concentrations correlated with clinical evolution in patients with ocular adnexal marginal zone B cell lymphoma associated with IgG4-related ophthalmic disease[ncbi.nlm.nih.gov] The regimen consisted of R (day 1), DOX, or THP (day 3), CPA (day 3), VCR (day 3), and PSL for 5 days every 3 weeks for 6 to 8 cycles.[ncbi.nlm.nih.gov]

  • Ependymoma

    KEYWORDS: Disease progression; Ependymoma; Prognosis; Second look surgery[ncbi.nlm.nih.gov] Late toxicity was assessed according to CTCAE v4.0.[ncbi.nlm.nih.gov] The current histopathology based WHO grading system distinguishes grade I, II 'classic', and III 'anaplastic' ependymoma.[ncbi.nlm.nih.gov] 3: Ependymoma, NOS (M-93913) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 2000-2019 progenetix.org Tooltip 9391/3: Ependymoma, NOS (M-93913) 1 25 75 75 25 50[progenetix.org] The Diseases Database is not a diagnostic or clinical decision-making tool. The medical information is intended for background reading and general interest.[diseasesdatabase.com] Tet proteins can oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine and 5-carboxylcytosine (5caC).[ncbi.nlm.nih.gov]